本帖最后由 老马 于 2013-3-13 13:43 编辑 $ z) S- L0 {3 A' e+ O4 _
7 C" t3 K% h+ P' c+ c* \
健择（吉西他滨）+顺铂+阿瓦斯汀
# k) W' G- @: m) J v. X, v Gemzar +Cisplatin + Avastin
5 g* q0 _4 C2 ^# F# I8 Bhttp://annonc.oxfordjournals.org/content/21/9/1804.full" H' @6 D7 \) H1 ^* m
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% o$ i0 P3 i' R/ d2 m* \Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 s% l' c: Q; _9 xResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 K' y# Y0 O/ ]4 @: `( ^! A2 O
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 611)
3 [- _. W+ n0 k. u2 u
华为网盘附件：
9 d: C9 ~/ q7 Z% x: t【华为网盘】ava.JPG
m1 n4 U* F$ B7 p3 \6 \$ M9 S/ d+ a' t |
显身卡
